9. BS09-23653 Dx: Chronic hepatitis, mildly active without significant scarring, compatible with hepatitis C Corresponds to: Modified Ishak stage 0/4 Metavir FO
16. BS09-12035 Dx: Chronic hepatitis, mildly active with focal fibrous septa, compatible with hepatitis C Corresponds to: Modified Ishak stage 2/4 Metavir F2
17. SS09-7396: Clinical history: 62 yo male. Chronic hepatitis C.
18.
19.
20.
21.
22. SS09-7396 Dx: Chronic hepatitis, mildly active with transition to cirrhosis, compatible with hepatitis C Corresponds to: Modified Ishak stage 3/4 Metavir F3 to F4
28. RS09-11796 Dx: Chronic hepatitis, mildly active with transition to cirrhosis, compatible with hepatitis C Corresponds to: Modified Ishak stage 3/4 Metavir F3-F4
29. BS09-23699 Clinical history: 57 yo, male. Hepatitis C, USG: possible liver mass .
59. 92-03086: 47 yo male, 3.5 years s/p OLT for Hepatitis B cirrhosis.
60.
61.
62.
63.
64. S07-20393 Dx: Liver Allograft: Needle Biopsy Recurrent hepatitis B, mildly active with focal fibrous septa. Comment: Immunostain for hepatitis B surface antigen confirms recurrent hepatitis B infection. Positive stain for core antigen confirms active viral replication. Corresponds to: Modified Ishak stage 2/4 Metavir: F2
65. RS09-11951: Clinical history : 68 yo female. Hepatitis B. AST 43, ALT 30. Grade and stage.
66.
67.
68.
69.
70. S07-20393 Dx: Liver: Needle Biopsy Chronic hepatitis B, minimally active with focal portal fibrosis. Comment: Immunostain for hepatitis B surface antigen confirms recurrent hepatitis B infection. The absence of staining for core antigen may relate to spontaneous or post-therapeutic clearance of virus, co-infection by hepatitis C or D, or sampling; clinical correlation required. Corresponds to: Modified Ishak stage 1/4 Metavir: F1
81. Case 91-2762: Clinical Hx: 34 yo, male, obese, with elevated LFTs (mild) and elevated ferritin.
82.
83.
84.
85.
86.
87. 91-2762: Dx: Steatosis, moderate, with rare foci of steatofibrosis (pericellular fibrosis). Comment: No histologic steatohepatitis or iron identified.
88. 91-22789: Clinical hx: 61 yo, male. ALT 59, Triglycerides 761, GGTP 240. R/O ETOH vs Fatty liver disease.
89.
90.
91.
92.
93.
94. 91-2762: Dx: Steatosis, severe, with marked steatohepatitis and steatofibrosis (transition to cirrhosis), ? alcoholic vs. non-alcoholic fatty liver disease. In kuwait….? “ Fatty liver disease, clinical correlation required for assessment of cause.”
95. 93-02583 42 yo, male with hyperlipidemia. No history of alcohol, diabetes or obesity.
96.
97.
98.
99.
100.
101. 93-02583: Dx: Steatosis, moderate to severe, with marked steatohepatitis and steatofibrosis (fibrous septa), compatible with hyperlipidemia-associated fatty liver disease.
102. S03-16834 53 yo male ALT elevation (1.5 – 2x upper limit of normal). 20 years of alcohol (2-3 daily, more on the weekend). USG: fatty liver.
103.
104.
105.
106.
107.
108.
109. S03-16834 Dx: Steatosis, severe, with mild steatohepatitis (see comment) and focal, mild steatofibrosis (perivenular and acinar zone 3 pericellular fibrosis, compatible with alcohol-related fatty liver disease. Comment: While the classical forms of steatohepatitis (i.e. hepatocyte ballooning, Mallory bodies, neutrophilic infiltrates) are not identified, the presence of focal, lobular and portal mononuclear infiltrates are probably indicative of some degree of steatohepatitis.
117. RFH case 2: 59 yo woman, obese, with abnormal liver tests for 2 years. She has non-insulin requiring DM. Hepatitis A, B and C negative. ANA and AMA negative. CT scan shows changes consistent with fatty changes.
118.
119.
120.
121.
122.
123. RFH case 2 Dx: Steatosis, severe, with moderate steatohepatitis and steatofibrosis (established cirrhosis) compatible with obesity related fatty liver disease.